




A



B



C



D




Figure S2 Sensitivity analysis of HR OS determined by the baseline ALBI grade before sorafenib treatment (A), HR OS determined by the baseline ALBI grade before regorafenib treatment (B), HR PFS determined by the baseline ALBI grade before sorafenib treatment (C), and HR PFS determined by the baseline ALBI grade before regorafenib treatment (D). HR, hazard ratio; OS, overall survival; ALBI, albumin-bilirubin; CI, confidence interval.